BeStock  

United Therapeutics UTHR

US equityMarket cap rank #819Drug Manufacturers - Specialty & Generic
$554.73 −$4.37 (-0.78%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $550.23 -0.81%
Open$561.20
Prev close$559.10
Day range$551.77 – $563.12
Volume531.8K
Market cap$23.63B
P/E (TTM)20.9
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership104.4%-0.59 pts vs. prior quarter
Institutions holding1,044-4 vs. prior quarter
Insider trades (recent)0 buys / 50 sellsNet selling
Short interest4.28% of floatDays to cover 3.5 · as of 30 Oct 2026
Short-sale volume share12.0%5-day average of daily volume

Short-sale volume as % of daily volume

5%12%19%26%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$3.66M (13 inflow days, 7 outflow days).

Net flow by order size, last 20 sessions

−$841.6KSuper+$4.5MBig+$29.5KMid+$37.5MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 33.8% of shares outstanding.

Largest holders

  • BlackRock13.09%
  • Avoro Capital Advisors LLC6.47%
  • Vanguard Capital Management, LLC5.17%
  • State Street Global Advisors4.58%
  • Vanguard Portfolio Management, LLC4.49%
  • Wellington Management Group4.46%
  • Renaissance Technologies Corp.3.94%
  • Amundi Asset Management2.32%

By investor type

  • Mutual Fund70.75%
  • Hedge Fund22.67%
  • Government Pension Fund3.12%
  • Public Company2.77%
  • Individual/Insider1.97%
  • Sovereign Wealth Fund1.72%
  • Private Company1.44%
  • VC/PE Fund0.99%

Reported short interest has fallen from 4.93% to 4.28% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Amundi Asset Management Mutual Fund 2026/Q4 +769,804 2.3%
Citadel Advisors LLC Hedge Fund 2026/Q4 +623,772 2.2%
Wellington Management Group Mutual Fund 2026/Q4 +520,580 4.5%
Invesco Capital Management LLC Mutual Fund 2026/Q4 +358,112 1.8%
BlackRock Mutual Fund 2026/Q4 +280,633 13.1%
Victory Capital Management Inc. Mutual Fund 2026/Q4 +226,239 0.6%
Deep Track Capital, LP VC/PE Fund 2026/Q4 +176,424 0.7%
Balyasny Asset Management L.P. Hedge Fund 2026/Q4 +114,730 0.3%
Longaeva Partners L.P. Mutual Fund 2026/Q4 +106,803 0.3%
First Trust Advisors L.P. Mutual Fund 2026/Q4 +100,610 0.8%
Swedbank Robur Fonder AB Mutual Fund 2026/Q4 +85,030 1.0%
Deerfield Management Company, L.P. Hedge Fund 2026/Q4 +83,598 1.3%
Eagle Health Investments LP Hedge Fund 2026/Q4 +79,678 0.2%
Caption Management, LLC Hedge Fund 2026/Q4 +76,401 0.2%
Arrowstreet Capital, Limited Partnership Mutual Fund 2026/Q4 +73,619 0.4%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
11 Nov 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $597.33 668,728
8 Nov 2026 Christopher Patusky Independent Vice Chairman & Lead Independent Director Derivative Exercise and Sale -1,210 $580.00 3,240
5 Nov 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $568.68 668,728
4 Nov 2026 Paul Mahon General Counsel Derivative Exercise and Sale -8,300 $602.72 45,172
2 Nov 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $605.97 668,728
1 Nov 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $598.84 668,728
29 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $608.05 668,728
28 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $599.30 668,728
27 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $588.39 668,728
26 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $592.84 668,728
25 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $592.92 668,728
22 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $588.00 668,728
21 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $590.40 668,728
20 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $566.43 668,728
19 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $563.56 668,728
18 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $556.88 668,728
15 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $543.85 668,728
14 Oct 2026 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $551.50 668,728
14 Oct 2026 Paul Mahon General Counsel Intent to Sell (Form 144) -8,300 $544.30 –
14 Oct 2026 Paul Mahon General Counsel Derivative Exercise and Sale -8,300 $546.56 45,172

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 1,837,654 4.3% 3.5
15 Oct 2026 2,457,723 5.7% 2.6
30 Sep 2026 3,596,948 8.4% 3.6
15 Sep 2026 2,800,470 6.5% 3.9
31 Aug 2026 2,059,685 4.8% 4.8
14 Aug 2026 2,112,367 4.9% 3.5

Discussion

No comments yet — be the first to weigh in on UTHR.

Sign in to join the discussion.

Scroll to Top